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Abstract Sudden cardiac death from ventricular fibril-
lation during myocardial infarction is a leading cause of
total and cardiovascular mortality. This multifactorial,
complex condition clusters in families, suggesting a
substantial genetic cause. We carried out a genomewide
association study (GWAS) for sudden cardiac death, in
the AGNES (Arrhythmia Genetics in the Netherlands)
population, consisting of patients with (cases) and
without (controls) ventricular fibrillation during a
first ST-elevation myocardial infarction. The most
significant association was found at chromosome
21q21 (rs2824292; odds ratio=1.78, 95% CI 1.47–
2.13, P=3.3×10−10), 98 kb proximal of the CXADR gene,
encoding the Coxsackie and adenovirus receptor. This
locus has not previously been implicated in arrhythmia
susceptibility. Further research on the mechanism of this
locus will ultimately provide novel insight into arrhythmia
mechanisms in this condition.
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Introduction
Sudden cardiac death (SCD) accounts for almost 20% of
total mortality in Western Europe and the USA, and
ventricular fibrillation (VF) is the most common underlying
arrhythmia [1, 2]. VF arises through multiple mechanisms,
depending on the underlying cardiac pathology. In the last
decade, considerable progress has been made in the
understanding of the genetic, molecular and electrophysio-
logical basis of SCD in the uncommon (monogenic)
familial arrhythmia syndromes affecting the structurally
normal heart and the rare inherited structural disorders
associated with increased SCD risk [3, 4]. However, the
overwhelming majority (~80%) of SCDs in adults are
caused by the sequelae of coronary artery disease, namely
myocardial ischaemia or acute myocardial infarction (MI)
[2], where SCD is the first clinically identified expression
of heart disease in up to half of cases [5]. In contrast to the
monogenic rhythm disorders, progress in understanding the
molecular determinants of VF in these conditions, affecting
a much greater proportion of the population, has been very
limited [6]. Consequently, specific and sensitive risk
predictors, as well as therapeutic targets for prevention,
are currently missing. Because of the magnitude of the
problem, the opportunities for a real public health impact of
improved risk stratification and novel preventive therapeu-
tic strategies are enormous. Even minor improvements
could reduce the number of victims significantly.
Heritability of SCD
The concept of a heritable component in the determination of
risk for SCD was first put forward by two epidemiological
studies published in the late 1990s. In a population-based case–
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control study in the Seattle area, the rate of MI or SCD among
first-degree relatives of cardiac arrest patients was almost 50%
higher than that in first-degree relatives of control patients [7]. In
the Paris Prospective Study, parental sudden death increased the
relative risk of SCD among French men to 1.8, and sudden
death of both parents increased the relative risk of SCD to 9.4
[8]. We subsequently analysed further the concept of genetic
predisposition to SCD in a case–control study in which we
selectively included only patients with a first, acute ST-
elevation myocardial infarction (STEMI). In this population,
recruited at multiple Dutch heart centres, which we named the
Arrhythmia Genetics in the NEtherlandS — AGNES — study,
we demonstrated that familial sudden death occurred signifi-
cantly more frequently among STEMI patients who suffered
VF (cases) compared with STEMI patients who did not suffer
VF (controls) (OR 2.72, 95% CI 1.84 to 4.03) [9]. This finding
provided a strong rationale for the search of genetic modulators
of risk in this specific cardiac pathology.
Nature of Genetic Variation Modulating Risk
VF during acute myocardial ischaemia can be regarded as a
complex, multifactorial phenotype. There are two prevail-
ing hypotheses as to the nature of the genetic variation
modulating such common phenotypes [10]. The ‘common
disease—common variant hypothesis’ implicates common
genetic variants, present at frequencies of >5% in the
general population, such as single nucleotide polymor-
phisms (SNPs), each conferring a small to modest risk. The
other hypothesis, the ‘rare variant hypothesis’, proposes
that susceptibility to common disease is due to low
frequency (<5%) variants, each conferring a moderate
increase in risk. The advent of arrays in the second half
of the last decade, capable of genotyping hundreds of
thousands of SNPs in an individual in one single
experiment, enabled the assessment of the contribution of
common genetic variation spread throughout the genome to
complex diseases. A clear advantage of these genomewide
association studies (GWAS) is that they are hypothesis-free,
as there is no bias or list of candidate genes that are being
tested. Genes previously unsuspected of being involved in
the disease can therefore also be identified.
AGenomewide Association Study of Ischaemia-Induced VF
In order to identify common genetic variation underlying
susceptibility to VF during a first acute MI, we recently
conducted a genomewide association study in the AGNES
case–control population [11]. The selection of one highly
specific arrhythmia phenotype (mechanism) — for instance
we excluded individuals with VF in the context of
extensive pre-existing myocardial scarring from previous
MIs—is critical in ensuring statistical power in such
association studies. We genotyped 515 AGNES cases with
VF and 457 AGNES controls without VF using the
Illumina Human610-Quad array. After quality control of
the genotype data, 507,436 SNPs were available for
analysis. Non-genotyped SNPs throughout the genome
were imputed by virtue of their degree of correlation to
genotyped SNPs using data from the HapMap European
CEU reference panel. The association of each SNP with VF
was then evaluated using logistic regression assuming an
additive genetic model with adjustment for age and sex.
Over 2 million SNPs were evaluated in this way.
The distribution of P values for the association of each
SNP with VF is shown in Fig. 1. Eight SNPs clustering on
chromosome 21q21 (the long arm of chromosome 21)
showed the strongest association signal, passing the
Bonferroni-corrected P value threshold of P<5×10−8. From
these, the most significant association signals were found
for rs2824292 and rs2824293 (P=3.3×10−10). These two
SNPs, which are highly correlated (in strong linkage
disequilibrium) with each other, exhibited an odds ratio of
1.78 per copy of the G allele (95% confidence interval,
1.47–2.13; risk allele was G for both SNPs). Approximately
30% of AGNES cases were homozygous for these alleles in
contrast to only 15% of AGNES controls. As expected, the
frequency of the risk alleles in the general population was
intermediate between those of cases and controls (Fig. 1).
Replication
One of the SNPs (rs2824292) was then carried forward for
replication in an independently recruited case–control set.
Cases for replication (n=150) were drawn from the
AmsteRdam REsuscitation Study (ARREST-11).
ARREST-11 is an ongoing prospective population-based
study aimed at establishing the genetic, clinical and
environmental determinants of SCD in the general popula-
tion. Caucasian out-of-hospital cardiac arrest patients in the
ARREST-11 dataset presenting with MI at hospital admis-
sion and with ECG-documented fast ventricular tachycardia
or VF were included in the replication analysis. Controls
for the replication analysis were MI survivors drawn from
the GENetic DEterminants of Restenosis (GENDER) study
[12] (GENDER-MI; n=391). The GENDER population
comprises consecutive patients who underwent successful
elective percutaneous transluminal coronary angioplasty at
one of four Dutch heart centres. As observed in the AGNES
case–control set, the risk G allele of SNP rs2824292 at
chromosome 21q21 was more abundant and the protective
A allele was less abundant in the ARREST-MI cases
compared with the GENDER-MI controls.
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Chromosome 21q21 in Arrhythmia Susceptibility
The chromosome 21q21 locus had not previously been
linked to arrhythmia and the mechanism by which common
genetic variation at this locus confers an increased risk to
VF is unknown. Common genetic variation is expected to
impact on disease either by changing the amino acid
sequence of a protein (and thereby its function) or by
impacting on the level of gene expression and consequently
protein level. The SNPs at chromosome 21q21 impacting
on risk for VF are not located within a gene. Inspection of a
1 megabase (Mb) interval spanning both upstream and
downstream of these SNPs identified three genes all located
within a region of 0.5 Mb downstream. One is BTG3,
located at a distance of 179 kb from the association signal.
This gene encodes B cell translocation gene 3, a member of
the PC3, BTG and TOB family of growth inhibitory genes
[13]. Its mRNA expression level is relatively high in the
testis, lung and ovary but is low in heart. Another gene in
the region is C21orf91, located at 374 kb from the
association signal; it encodes the human orthologue of the
chicken C21orf91 (also known as EURL, encoding the
early undifferentiated retina and lens protein), which is
known to be expressed in the developing chick retina and
lens and has been suggested to play a role in the
development of these structures [14].
The most plausible candidate gene in the region for the
observed effect at this locus is, however, the CXADR gene,
located 98 kb downstream of the association signal. This
gene encodes the Coxsackievirus and adenovirus receptor
(CAR) protein, which is mostly expressed in the heart, brain
and pancreas [15]. CAR has a long-recognised role as viral
receptor in the pathogenesis of viral myocarditis and its
sequela of dilated cardiomyopathy [16, 17]. Upon infection,
the enteroviral (as is the Coxsackie B virus) protease 2A
cleaves dystrophin, resulting in disruption of the dystrophin–
glycoprotein complex, a component of the cytoskeleton of
cardiac myocytes [18]. Interestingly, frequency of active
Coxsackie B virus infection has been reported to be high in a
group of MI patients who died suddenly [19]. The physio-
logical role of CAR was initially less clear. It is expressed at
the intercalated disc between cardiomyocytes, suggesting a
role in conduction of the cardiac electrical impulse and
cell–cell communication [20, 21]. Indeed, two studies
have reported a physiological role for CAR in localisation
of connexin 45 at the intercalated disks of atrioventricular
node cardiomyocytes as well as its role in conduction of
the cardiac impulse within this cardiac compartment [22,
23]. In addition, protein levels of connexin 43, which is
expressed in atrial and ventricular myocytes and in distal
parts of the conduction system, were reduced in CAR-
deficient mice, suggesting that loss of CAR could impact
on ventricular conduction [23]. Thus, CXADR is a
candidate gene for the association reported here.
However, providing support for a role of CXADR (or any
other gene) in mediating the observed effect is a daunting
task. The SNPs mediating the association signal on chromo-
some 21q21 are not linked to amino acid changing variants
within the CAR coding region (or any other gene in the
98.3 Kb
rs2824292 CXADR
Fig. 1 Results of genomewide association analysis in the AGNES
case–control population. a Manhattan plot of the genomewide
association scan in the AGNES population. Each dot represents a
different SNP, with the alternating bands of colour showing different
chromosomes of the human genome (X axis). The negative logarithms
of the P values, expressing the strength of the association, are
displayed on the Y axis. P values are corrected for age, sex and
inflation factor. The horizontal red line indicates the preset threshold
for genomewide significance, P<5×10−8. Data drawn from Bezzina et
al. [11]. b Distribution of rs2824292 genotypes in the discovery set,
the replication set and a sample of the general population. c
Haploview plot of linkage disequilibrium (D′) for all CEU HapMap
SNPs in the region harbouring rs2824292 and the CXADR gene.
Colour scheme: D′=1 and LOD≥2 bright red, D′<1 and LOD≥2
shades of pink/red, D′=1 and LOD<2 blue, D′<1 and LOD<2 white
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region). This precludes an effect through functional variation
of a gene product, implying that the role of these SNPs in
modulation of arrhythmia risk is to be sought in effects on
gene expression. Effects of common genetic variation on
gene expression is considered to be an important mechanism
impacting on inter-individual variation in disease suscepti-
bility, and many GWAS studies have in fact identified many
signals within non-coding (intronic and intergenic) regions
[24]. This will require studying gene expression as a function
of genotype at this locus in the human heart.
Conclusion and Future Directions
It is clear that other genetic variation in other areas of the
genome will impact on risk of VF during acute ischaemia.
These loci, as for the one we identified, are expected to
carry small effect sizes, implying that increased numbers of
AGNES cases and controls will be required to uncover
additional genes by GWAS. For this reason, recruitment of
AGNES cases and controls is ongoing.
The risk carried by the common genetic variation we
identified at chromosome 21q21 is small, meaning that
genotyping of this locus alone for risk stratification in
patients will not reach the accuracy that is considered as
clinically informative. Nevertheless, if additional such loci
are identified, one could envisage that by virtue of their
additive effect, genotyping of such variants at multiple loci
may in the future lead to their use in clinical practice.
Importantly, however, the GWAS approach we used here
has revealed a previously unsuspected involvement of
chromosome 21q21 in arrhythmia risk. Further research
on the mechanism of this locus will ultimately provide
novel insight into arrhythmia mechanisms in this condition.
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